Liver Cirrhosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Liver Cirrhosis - Pipeline Review, H2 2018’, provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis

- The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects

- The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlfaSigma SpA

Bristol-Myers Squibb Co

Galectin Therapeutics Inc

Gilead Sciences Inc

Grifols SA

International Stem Cell Corp

MallInckrodt Plc

Mina Therapeutics Ltd

Novartis AG

Pharmicell ...

AlfaSigma SpA

Bristol-Myers Squibb Co

Galectin Therapeutics Inc

Gilead Sciences Inc

Grifols SA

International Stem Cell Corp

MallInckrodt Plc

Mina Therapeutics Ltd

Novartis AG

Pharmicell Co Ltd

Rohto Pharmaceutical Co Ltd

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Cirrhosis – Overview

Liver Cirrhosis – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Cirrhosis – Overview

Liver Cirrhosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Cirrhosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Cirrhosis – Companies Involved in Therapeutics Development

AlfaSigma SpA

Bristol-Myers Squibb Co

Galectin Therapeutics Inc

Gilead Sciences Inc

Grifols SA

International Stem Cell Corp

MallInckrodt Plc

Mina Therapeutics Ltd

Novartis AG

Pharmicell Co Ltd

Rohto Pharmaceutical Co Ltd

VESSL Therapeutics Ltd

Liver Cirrhosis – Drug Profiles

7-E – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADR-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

albumin (human) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-800 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986036 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Cirrhosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-LC – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXHPC-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTL-CEBPA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-654 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit C/EBP-Beta for Gastrointestinal and Respiratory Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRI-724 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin SSD – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLY-012 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Cirrhosis – Dormant Projects

Liver Cirrhosis – Discontinued Products

Liver Cirrhosis – Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Exalenz Bioscience’s Non-Invasive BreathID Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

Apr 18, 2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018

Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis

Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial

Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Liver Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Liver Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Liver Cirrhosis – Pipeline by AlfaSigma SpA, H2 2018

Liver Cirrhosis – Pipeline by Bristol-Myers Squibb Co, H2 2018

Liver Cirrhosis – Pipeline by Galectin Therapeutics Inc, H2 2018

Liver Cirrhosis – Pipeline by Gilead Sciences Inc, H2 2018

Liver Cirrhosis – Pipeline by Grifols SA, H2 2018

Liver Cirrhosis – Pipeline by International Stem Cell Corp, H2 2018

Liver Cirrhosis – Pipeline by MallInckrodt Plc, H2 2018

Liver Cirrhosis – Pipeline by Mina Therapeutics Ltd, H2 2018

Liver Cirrhosis – Pipeline by Novartis AG, H2 2018

Liver Cirrhosis – Pipeline by Pharmicell Co Ltd, H2 2018

Liver Cirrhosis – Pipeline by Rohto Pharmaceutical Co Ltd, H2 2018

Liver Cirrhosis – Pipeline by VESSL Therapeutics Ltd, H2 2018

Liver Cirrhosis – Dormant Projects, H2 2018

Liver Cirrhosis – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Liver Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Liver Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports